









Markets
/
Stocks
/
nasdaq-bhc
/

Bausch Health Companies Inc

BHC

6.849USD

+0.449+7.02%

Market hours （ET）Quotes delayed by 15 min

2.54BMarket Cap

7.01P/E TTM



Bausch Health Companies Inc

6.849

+0.449+7.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bausch Health Companies Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bausch Health Companies Inc's Score

Industry at a Glance

Industry Ranking

103 / 159

Overall Ranking

274 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Hold

Current Rating

7.167

Target Price

+7.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bausch Health Companies Inc Highlights

StrengthsRisks

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.48% year-on-year.

Overvalued

The company’s latest PE is 6.54, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 179.04M shares, decreasing 33.04% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.72.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 8.35, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 2.68B, representing a year-over-year increase of 6.81%, while its net profit experienced a year-over-year increase of 310.59%.

Score

Industry at a Glance

Previous score

8.35

Change



Financials

5.53

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.26

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.51

Key Metrics

Free cash flow

No Data

Bausch Health Companies Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 5.04, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 6.54, which is 381.30% below the recent high of 31.47 and 1086.22% above the recent low of -64.48.

Score

Industry at a Glance

Previous score

5.04

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 103/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 5.67, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Bausch Health Companies Inc is 7.00, with a high of 10.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

5.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Hold

Current Rating

7.167

Target Price

+11.98%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Bausch Health Companies Inc

BHC

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 6.99, which is lower than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 7.09 and the support level at 5.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.36

Change

-0.37

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.088

Neutral

RSI(14)

47.545

Neutral

STOCH(KDJ)(9,3,3)

51.568

Sell

ATR(14)

0.335

High Vlolatility

CCI(14)

0.841

Neutral

Williams %R

59.615

Sell

TRIX(12,20)

0.149

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

6.652

Buy

MA10

6.579

Buy

MA20

6.373

Buy

MA50

6.626

Buy

MA100

6.669

Buy

MA200

6.284

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Paulson & Co. Inc.

Star Investors

70.76M

+115.77%

Meruelo (Alex)

36.76M

+0.41%

GoldenTree Asset Management, LP

34.25M

+13.24%

Nomura Securities Co., Ltd.

21.50M

-8.12%

Healthcare Of Ontario Pension Plan

13.00M

The Vanguard Group, Inc.

Star Investors

11.70M

+0.20%

Maple Rock Capital Partners, Inc.

7.81M

+14.87%

National Bank of Canada

7.74M

+3.06%

MFN Partners Management LP

6.00M

Kohlberg Kravis Roberts & Co. L.P.

5.24M

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 4.27, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.